Clinical trialObsUnknown
Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients
- Outcome
- Outcome unknown
- Phase
- Obs
- Status
- Unknown
- Study type
- Observational
- Start
- 1 March 2024
- Expected end
- 1 September 2026
- Enrollment
- 40 participants
- Sites
- 1
- Primary outcomes
- Bioinformatics analysis of single-cell sequencing results
- Sponsor
- Other
- Results posted
- No
- Last update
- 15 March 2024
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 2
- BackgroundNeoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-T… DOI 10.1200/jco.21.02233↗
- BackgroundPreoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Res… DOI 10.1200/jco.19.02274↗